12 recruiting. 12 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Recruiting 12 |
| Phase 1 | 2 | Recruiting 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Hematologic Malignancies: new trials by email Literature Review of Hematologic Malignancies trials Research Report on Hematologic Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention Cyclophosphamide (primary intervention for GVHD prophylaxis) - Graft-versus-Host Disease (GVHD), Hematologic Malignancies | Phase 2 | Recruiting | Milton S. Hershey Medical Center | 41 | 2026-03-09 | 2026-04-03 |
| A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant Cyclophosphamide, Mycophenolate Mofetil, Ruxolitinib - Hematologic Malignancies | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2026-01-20 | 2026-07-07 |
| PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) PUL-042, Placebo - Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT) | Phase 2 | Recruiting | Pulmotect, Inc. | 100 | 2025-06-27 | 2026-08-04 |
| Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation Drugs Cyclophosphamide, Fludarabine, Thiotepa - Hematologic Malignancies | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 35 | 2025-03-03 | 2026-04-28 |
| Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients Leflunomide 20 mg - Hematologic Malignancies | Phase 2 | Recruiting | Tata Memorial Centre | 22 | 2024-10-18 | 2026-07-16 |
| IVIG for Infection Prevention After CAR-T-Cell Therapy Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline - Hematologic Malignancies | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 150 | 2024-06-10 | 2026-06-29 |
| ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) ICP-248, Orelabrutinib - Hematologic Malignancies | Phase 2 / Phase 3 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 226 | 2024-05-15 | 2025-11-21 |
| Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Fludarabine, Melphalan, Total Body Irradiation - Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation | Phase 2 | Recruiting | University of California, Irvine | 60 | 2023-09-11 | 2026-02-02 |
| Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... RIC, GVHD prophylaxis, allo HCT - HIV, Hematologic Malignancies | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 265 | 2023-01-26 | 2026-10-16 |
| Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab Tafasitamab - Hematologic Malignancies | Phase 2 | Recruiting | Incyte Corporation | 25 | 2022-11-08 | 2025-12-10 |
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML SLS009, venetoclax, azacitidine - Hematologic Malignancies | Phase 1 / Phase 2 | Recruiting | Sellas Life Sciences Group | 160 | 2021-05-10 | 2026-09-03 |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) Nemtabrutinib - Hematologic Malignancies, Waldenstroms Macroglobulinaemia | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 490 | 2021-04-05 | 2026-10-27 |
Hematologic Neoplasms (12) · Graft vs Host Disease (2) · Acquired Immunodeficiency Syndrome (1) · Leukemia, B-Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Recurrence (1) · Waldenstrom Macroglobulinemia (1)
Hematologic Diseases (12) · Hemic and Lymphatic Diseases (12) · Neoplasms (12) · Neoplasms by Site (12) · Immune System Diseases (5) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms by Histologic Type (2) · Blood Protein Disorders (1) · Blood-Borne Infections (1) · Cardiovascular Diseases (1) · Chronic Disease (1)
Mycophenolic Acid (3) · Tacrolimus (3) · Cyclophosphamide (2) · fludarabine (2) · ARQ531 (1) · Azacitidine (1) · Leflunomide (1) · Maraviroc (1) · Melphalan (1) · Pam2CSK4 acetate and ODN M362 combination (1) · Sodium Chloride (1) · Solutions (1) · Thiotepa (1) · Whole-Body Irradiation (1) · orelabrutinib (1)
Beijing InnoCare Pharma Tech Co., Ltd. (1) · Fred Hutchinson Cancer Center (1) · Incyte Corporation (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Merck Sharp & Dohme LLC (1) · Milton S. Hershey Medical Center (1) · National Cancer Institute (NCI) (1) · Pulmotect, Inc. (1) · Sellas Life Sciences Group (1) · Tata Memorial Centre (1) · University of California, Irvine (1)
United States (9) · China (3) · Hungary (2) · Italy (2) · South Korea (2) · Spain (2) · Turkey (Türkiye) (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1)
Colin Broom, MD (1) · Doris Ponce, MD, MS (1) · Dragan Cicic, MD (1) · Joseph Cioccio, MD (1) · Joshua Hill, MD (1) · Mustafa A Hyder, M.D. (1) · Stefan O. Ciurea, MD (1) · Warren Fingrut, MD (1)
PMID 10515382, PMID 10573044, PMID 12659416, PMID 15528753, PMID 15845896, PMID 18307672, PMID 19955306, PMID 20837781, PMID 22093814, PMID 23146063, PMID 25790744, PMID 25949314, PMID 27047808, PMID 27418009, PMID 27682069, PMID 28544502, PMID 28986189, PMID 29190347, PMID 29211658, PMID 31054984, PMID 31153807, PMID 32017805, PMID 32202631, PMID 34305463
2023 (1), R01CA276040 (1)